Professor Woo-Joo Kim “The effect of lowering the mortality rate cannot be announced…it is not enough for a game changer”
Celltrion “To lower the mortality rate, we need to stop severe transition”
Amid rising expectations for Celltrion’s new coronavirus infection (Corona 19) antibody treatment, some pointed out that it is difficult to view this drug as a’game changer’.
Kim Woo-joo, a professor of infectious medicine at the ancient Guro Hospital, said on YouTube on the 14th, “It is not enough to say that it is a’game changer’ because the effect of lowering the mortality rate (Celltrion antibody treatment) has not been announced.”
Prof. Kim pointed out that the results of the Phase 2 clinical trial of Celltrion’s antibody treatment “Recyronaju” (ingredient name regdanvimab code name CT-P59), which were released the day before, did not contain any information on the study method, but only the results.
Professor Kim said, “In any study, the characteristics of the people who received treatment included in the study should be equal in both groups (placebo group and test group),” said Professor Kim. “Yesterday, only the results of the study were reported, so it may be overinterpreted than it is. “He said.
Prof. Kim also added, “It is only possible to determine whether the results are meaningful only in the third phase of clinical trials, but it is difficult to accurately evaluate them only by looking at the press release yesterday.”
“In order to reduce the mortality rate, it is necessary to recover as soon as possible without going to severe disease,” said Sang-jun Lee, senior vice president of clinical trial at Celltrion. We are also considering one clinical trial.”
Senior vice president Lee also said, “There is no problem with the balance between the placebo group and the test group.”
Professor Kim also pointed out that it may be difficult to cope with mutant viruses due to the nature of monoclonal (monoclonal) antibody treatments.
Celltrion’s Rekironaju is a monoclonal antibody treatment made by selecting only antibodies that can neutralize the virus by binding to the spike protein on the surface of the virus in the blood of the plasma of a person who has cured Corona 19.
Professor Kim said, “Unfortunately, if a virus mutation occurs in the area where the antibody treatment is attached, the antibody does not adhere well, and the efficacy will decrease.”
Professor Kim explained that vaccines and antiviral drugs are unlikely to be less effective in mutations.
Professor Kim said, “Vaccines are a mechanism by which our immune system makes countless antibodies by inoculating spike proteins as antigens, and antiviral agents block the function of protein (RdRP) that replicates viruses.”
yunhap news